Postcards from BIO: Observations on Start-Up Financing and Dealmaking
This article was originally published in Start Up
Executive Summary
This year's annual Biotechnology Industry Organization was chock-full of angst, with biotech clearly in a contraction amid bankruptcies, scarce financing, and few exits in sight. START-UP was there to chronicle some of the technological and financial highlights, to gauge the pulse of industry, and to talk to a variety of biotech and pharmaceutical executives about the future of biotech dealmaking. Snapshots here include the unveiling of Adimab's platform, the NIH's new bridge funding option; and a positive message on anti-infectives development . More of our BIO coverage can be found on The IN VIVO Blog (http://invivoblog.blogspot.com).